Neoleukin Therapeutics is a biopharmaceutical company creating immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Co. is initially focused on key cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. Co.'s primary product candidate, NL-201, is a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin-2, or IL-2, and interleukin-15, or IL-15, for the potential treatment of various types of cancer, including renal cell carcinoma and melanoma, while limiting the toxicity caused by the preferential binding of native IL-2 and IL-15 to non-target cells. The NLTX stock yearly return is shown above.
The yearly return on the NLTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NLTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|